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Response to endocrine manipulation and oestrogen receptor
concentration in large operable primary breast cancer
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Summary Forty-three patients with large (>4cm) but operable carcinoma of the breast have been treated by
endocrine manipulation before definitive local surgery. This has allowed the study of the relationship between
response to therapy and pretreatment oestrogen receptor (ER) concentration, as measured by a dextran-
coated charcoal adsorption method. Premenopausal patients (17) were treated by surgical (4) or medical (13)
oophorectomy. Post-menopausal patients (26) received either tamoxifen (10) or an aromatase inhibitor (16).
Response was assessed from statistical analysis of the changes in tumour size. On completion of 12 weeks of
endocrine therapy, there was significant regression of tumour size in 18 of the 43 patients. All 18 patients had
tumours with ER concentrations of >20fmolmg- cytosol protein. Conversely all patients except one
progressing on treatment had tumours with ER concentrations of <20fmolmg- 1 cytosol protein. This
relationship applied for both premenopausal and post-menopausal patients. The overall response rate of
patients with tumours of ER concentration >20fmolmg-1 cytosol protein was 60%.
The likelihood of response to endocrine treatment in patients
with metastatic breast carcinoma is related to the concent-
ration of oestrogen receptor (ER) protein within that tumour
(McGuire et al., 1975; Brooks et al., 1980; Jensen, 1975; Dao
& Nemoto, 1980; Oriana et al., 1987). The value of ER
status in predicting benefit from adjuvant endocrine treat-
ment remains controversial. While several studies have
demonstrated that only patients with ER-positive tumours
have a significant survival advantage (Rose et al., 1985;
Fisher et al., 1986; Rutquist et al., 1987; Meakin, 1986;
Marshall et al., 1987; Bianco et al., 1988), the Nato trial
(Nolvadex Adjuvant Trial Organisation, 1988) has indicated
that the benefit is independent of ER status. An intermediate
view has been suggested by the Scottish (Scottish Cancer
Trials Office (MRC) Edinburgh, 1987) and Copenhagen
(Palshof et al., 1985) trials, in which all patients who
received tamoxifen benefited but the level of benefit was
greatest in those patients with tumours of an ER concent-
ration of > 100fmol mg- 1 cytosol protein. Thus the rela-
tionship between ER concentration and response of primary
operable breast cancer to endocrine treatment remains
uncertain.
We have previously reported (Forrest et al., 1986) that the
response of large but operable breast cancer to systemic
therapy can be measured with precision. By obtaining a
small piece of tumour before initiating systemic therapy,
response can be related to the specific biochemical and
histological parameters of an individual primary tumour.
This paper describes the relationship between the ER con-
centration of large primary operable breast cancer and their
response to endocrine treatment.
Materials and methods
Patient population
Between April 1985 and December 1987, 43 patients with
primary operable breast cancer of mean clinical diameter
greater than or equal to 4cm were given endocrine therapy
for 3 months before definitive local surgery. Initially all
patients (n=35) were given endocrine therapy irrespective of
the ER concentration of their tumour. In April 1987,
however, there was a change in policy resulting from review
of the results and only those patients with tumours of ER
concentration of greater than 20fmolmg-1 cytosol protein
received primary hormonal manipulation (n =8). Patients
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with tumours of ER concentration 20fmolmg-1 cytosol
protein or less were given four cycles of the chemothera-
peutic regime CHOP (cyclophosphamide 1 gm-2, adriamycin
50mgm-2, vincristine 1.4mgm-2, prednisolone 40mg orally
5 days).
Patients over 70 years of age, with a history of psychiatric
instability or evidence of metastatic disease on clinical,
haematological, biochemical or bone scintiscan investigation
were excluded from the study. Seventeen patients were
premenopausal, 26 were post-menopausal, i.e. more than 1
year since their last menstrual period.
Initial assessment
At initial presentation, tumour size was assessed from both
clinical and radiological examination. The mean clinical
diameter was calculated from the mean of eight caliper-
measured diameters taken at 22.5° axes. An incisional wedge
biopsy was performed under general anaesthesia and 0.6cm3
of tumour removed and sent for histological and biochemical
evaluation.
The determination of oestrogen receptor concentration
The ER concentration of the excised tumour specimen was
determined using the dextran-coated charcoal adsorption
method (Hawkins et al., 1981). In brief, tumour was homo-
genised in tris-monothioglycerol-glycerol buffer and centri-
fuged at low speed; portions of tumour extract were
incubated at 4°C overnight with eight concentrations of 3H
oestradiol + non-radioactive oestradiol (0.031-62.3 nM).
After separation of the bound fraction by adsorption with
dextran-coated charcoal and scintillation counting, the con-
centration of receptor sites and dissociation constant of
binding were calculated by Scatchard analysis (Scatchard,
1949) using a programmed BBC microcomputer. Protein
concentration was determined in a separate portion of each
tumour extract by the method of Bradford (Bradford, 1976)
using serum albumin as a standard, with five quality
controls. Receptor concentration was finally expressed as
femtomol of binding sites per mg extract protein. Quality
controls consisting of pools of minced human uterus were
processed at least twice per week. Intra-assay precision was
3.9% but inter-assay precision was modest (25.1%, 33.6%
on two tissue pools (Hawkins et al., 1987a)).
Endocrine treatment
In premenopausal patients (n= 17), suppression of ovarian
function was achieved by either surgical bilateral oophorec-
tomy (n =4) or the administration of the gonadotrophin
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releasing-hormone agonist gosereliu (Zoladex; ICI 118630,
subcutanesus implantation of 3.6mg depot preparation at 28
day intervals, n = 13).
Post-menopausal patients (n =26) received either tamoxi-
fen (20mg oral nocte, n =10), or an aromatase inhibitor
(n= 16). Initially aminoglutethimide 500mg plus hydrocorti-
sone 40mg orally per day (n =9) was used, but recently the
selective peripheral aromatase inhibitor 4-hydroxy-
androstenedione (Ciba-Geigy CGP 32349, 250mg intramus-
cular injection at 14-day intervals, n=7) has been preferred.
Assessment
During treatment, the patients were reviewed weekly by
either EA or PL and the mean clinical tumour diameter was
estimated. Single view mammography, in the plane known to
give the best view of the tumour, was performed every 4
weeks.
Calculation of response
Assessment of response was carried out at 12 weeks by
analysis of the change in mean tumour diameter, as des-
cribed previously (Forrest et al., 1986) with one refinement:
the measurements recorded between treatment weeks I and 3
were disregarded to minimise any error introduced by the
wedge biopsy. In brief, a regression line was calculated by
least square analysis of the logs of the mean clinical
diameters measured between treatment weeks 4 and 12
(Figure 1). The statistical difference between the regression
line and the horizontal was ascertained by application of
Student's t test. Response was said to have occurred when
there was a reduction in tumour size, and the probability
that the regression slope deviated from the horizontal was
>95%. The appearance of lymphoedema, or a statistically
significant increase in tumour size, indicated progression.
Tumours with regression slopes which lay between response
and progression were categorised as 'no change'.
Local therapy
Those patients who had shown a response to endocrine
treatment proceeded on to mastectomy with extensive skin
removal (3cm clear of original tumour site), axillary node
clearance and a latissimus dorsi myocutaneous flap recon-
struction when required. Patients whose tumour remained
static or in whom treatment required to be prematurely
terminated due to progressive disease received four cycles of
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Figure 1 Response graph of a premenopausal patient with a
primary operable breast cancer of ER concentration
23 fmolmg- cytosol protein following the administration of the
gonadotrophin-hormone releasing-hormone Zoladex. This was
given by subcutaneous implantation of a depot preparation at
28-day intervals as indicated by the arrows. Each point repre-
sents a mean clinical diameter while each square is the mean
mammographic diameter calculated from a single view mammo-
gram. The calculated regression line had a correlation coefficient
of -0.8 and a slope of -3 x 10-3cm(log)day- This indicates
statistically significant regression (P<0.01, Student's t test).
the chemotherapeutic regime CHOP before also proceeding
to mastectomy.
Results
The spectrum of tumour ER concentrations in these
patients is shown in relation to four subgroups (ER-negative
0-5 fmolmg-1 cytosol protein, ER-poor 5-19 fmolmg-1 cyto-
sol protein ER-moderate 20-99fmolmg-1 cytosol protein
and ER-rich >100fmolmg-1 cytosol protein) in Table I. The
median ER concentration in premenopausal patients was
lower (30fmolmg-1 cytosol protein) than in the post-
menopausal group (158fmolmg-1 cytosol protein), a reflec-
tion of the higher fraction of post-menopausal patients with
ER-rich tumours. The proportion of patients within each
menopausal group with ER-negative or ER-poor tumours
was similar at around 30%.
Response rates
Eighteen of 43 patients (42%) had significant regression of
their primary tumour following endocrine therapy (Tables II
and III). The overall response rate for post-menopausal
patients was slightly higher than for premenopausal patients
(46% vs35%) (Table I) but this difference was not significant
(X2 =0.09, P=0.8). The relationship between ER concen-
tration and response is shown in Figure 2. Although there
was considerable overlap between groups, a significant rela-
tionship between ER concentration and the likelihood of
response to endocrine therapy existed (Spearman rank corre-
lation coefficient r=0.65, P<0.0001). All patients who res-
ponded to treatment had tumours with an ER concentration
of greater than 20fmolmg-1 cytosol protein. Conversely all
Table I Response to endocrine therapy in relation to ER concent-
ration and menopausal status in 43 patients with large but operable
primary breast cancer
No. patients responding/total
ERa %responding
subgroup Premenopausal Post-menopausal total
<5 0/2 0/5 0
5-19 0/3 0/3 0
20-99 6/11 2/4 53
>_100 0/1 10/14 67
Total 6/17 12/26 42
afmolmg 1 cytosol protein.
Table II Clinical mean tumour diameters at treatment weeks 4 and
12 of the 18 patients who responded to endocrine therapy
Clinical mean tumour diameter (cm)
Patient
E.F.
M.H.
M.W.
M.F.
J. McF.
I.C.
A.P.
M.D.
J.C.
A.A.
P.G.
E.A.
H.C.
J.A.
E.B.
W.S.
J.E.
M.F.
Week 4
4.75
3.6
4.0
3.6
3.1
5.4
4.6
3.6
4.3
3.6
4.0
5.0
4.1
4.1
4.3
3.5
4.2
6.9
Probability of
Week 12 regression
3.7
2.0
3.1
2.9
2.1
4.2
3.6
2.5
3.4
2.5
2.4
4.2
2.9
0
2.7
3.0
3.6
2.0
0.01
0.003
0.05
0.05
0.03
0.01
0.002
0.04
0.02
0.004
0.00008
0.01
0.001
a
0.004
0.03
0.00008
0.0007
aDenotes no P value available due to too few degrees of freedom
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patients who progressed on treatment, except one, had
tumours with an ER concentration of less than 20fmolmg-1
cytosol protein (Figure 3). This relationship held true for
both premenopausal and post-menopausal patients.
Relationship between response and disease-free survival
With a mean follow-up period of 40.6 months, eight patients
have developed recurrent disease; two patients who res-
ponded to endocrine therapy and six patients who did not.
Clinical response is related to disease-free survival in Figure
3. Using the generalised Wilcoxon (Breslow) survival test,
there was a statistical significant difference in survival
between those patients who showed a response to endocrine
treatment and those who did not (P<0.05).
Table III Response rates of 43 patients with large operable breast
carcinoma treated with primary endocrine therapy
ER <20a ER>20a
Total (no. patients (no. patients
no. of responding/ responding/
patients total) total)
Premenopausal
Oophorectomy 4 0/2 1/2
GnRH analogue 13 0/3 5/10
Total 17 0/5 6/12
Post-menopausal
Tamoxifen 10 0/4 4/6
Aminoglutethimide 9 0/4 4/5
4-Hydroxyandrostenedione 7 - 4/7
Total 26 0/8 12/18
Grand total 43 0/13 18/30
afmolmg- 1 cytosol protein.
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Figure 2 The relationship between the pretreatment ER con-
centration in 43 patients with primary operable carcinoma of the
breast and clinical response to 3 months' treatment with endo-
crine therapy. The ER concentration was determined by the
dextran-coated charcoal adsorption method. Response was
assessed from statistical analysis of the regression slope (Student's
t test, see text). The median ER concentration in each response
group is shown by a bar. Open circles have been used to denote
tumours from premenopausal patients and closed circles tumours
from post-menopausal patients.
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Figure 3 The relationship between disease-free survival and
response to endocrine therapy in 43 patients with large but
operable primary carcinoma of the breast. With a mean follow-
up period of 40.6 months (range 7-43 months), there is a
statistically significant difference in the survival of those patients
who responded to treatment when compared to those who did
not (P<0.05, generalised Wilcox (Breslow) survival test).
Discussion
This report confirms and expands our previous reports
(Forrest et al., 1986; Hawkins et al., 1988; Anderson et al.,
1989) of the relationship between ER concentration and
response to endocrine therapy in primary operable breast
cancer. Primary tumours with an ER concentration of less
than 20fmolmg-1 cytosol protein did not respond to endoc-
rine therapy, while 60% of those with higher ER values did.
Using an immunocytochemical assay we have observed a
similar relationship between ER status and response of
primary tumours in elderly women treated with tamoxifen
(Gaskell et al., 1989). Considering that this relationship also
exists for metastatic disease (McGuire et al., 1975; Brooks et
al., 1980; Jensen, 1975; Dao & Nemoto, 1980; Oriana et al.,
1987), it is reasonable to expect that ER concentration
should be of value in selecting appropriate adjuvant endoc-
rine therapy. We have already discussed the confusion which
surrounds the value of ER activity in predicting benefit with
adjuvant tamoxifen. In vitro studies have suggested that
tamoxifen may have antitumour actions which are indepen-
dent of the oestrogen receptor (Sutherland et al., 1986) and
can be distinguished from nonspecific cytotoxicity by its cell
cycle specific nature (Sutherland et al., 1983). Thus results
obtained using adjuvant tamoxifen cannot necessarily be
extrapolated to other forms of endocrine therapy, e.g.
oophorectomy. Further definition of the role of ER activity
in predicting the benefit from adjuvant endocrine therapy is
obviously required. This can only come from well conducted,
controlled randomised trials designed specifically to answer
this question and in which the performance of ER assays is
of uniform high quality.
Systemic therapy is of major importance in the long term
control of invasive breast cancer because of the high possi-
bility of micrometastatic disease at the time of initial presen-
tation (Brinkley & Haybittle, 1984). Since it is not yet
possible to predict, on an individual basis, those patients
who will benefit from a specific form of systemic therapy,
there is theoretical value in giving systemic therapy as the
preferred first line treatment. This would enable the response
of the individual's tumour to be assessed and allow selection
of appropriate systemic therapy. The availability of fine-
needle aspiration techniques for diagnosis (Dixon et al.,
1984) and more recently ER assay (Coombes et al., 1987;
Hawkins et al., 1988; Anderson et al., 1989; Gaskell et al.,
1989) should lend feasibility to this approach, avoiding the
need for open biopsy.
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